Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting


https://finance.yahoo.com/news/gamida-cell-presents-data-nicotinamide-130000652.html

BOSTON, November 09, 2021--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced data evaluating the mechanism of action of nicotinamide (NAM)-enabled NK cells, demonstrating enhanced homing, cytotoxicity and tumor reduction by GDA-201, the lead candidate in its NAM-enabled NK cell therapy pipeline. The data will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) taking place in Washington, DC, and virtually November 10-14, 2021.

The presentations identify network interactions between differentially expressed genes and intracellular metabolites associated with enhanced biological functional activity of GDA-201 NK. The data show that NAM increases cytotoxicity, ADCC, homing and in vivo antitumor activity of NK cells by modulating multiple metabolic pathways, down-regulating immune checkpoint inhibitors, increasing resistance to reactive oxygen species and influencing other cellular processes. An artificial intelligence–assisted analysis identified 1,204 differentially expressed genes, and 100 significantly modified metabolites, due to the effect of NAM. These data further validate the unique benefits of the NAM technology and its potential to improve clinical outcomes.

"NAM gives us a powerful tool for preserving and enhancing desirable qualities of NK cells and a broad range of other cell types. It has been shown to improve persistence and potency against cancer and may offer advantages in overcoming an immunosuppressive tumor microenvironment," said Julian Adams, Ph.D., chief executive officer of Gamida Cell. "These data are helping us to better understand how our proprietary NAM technology platform produces these benefits as we continue to pursue clinical trials of GDA-201 and other NK cell therapies."

Gamida Cell will present two posters at the conference, entitled "Cytotoxicity of nicotinamide (NAM)-enhanced natural killer (NK) cells (GDA-201) is based on metabolic modulation as demonstrated by artificial intelligence–assisted analysis of NK cell transcriptome and metabolome," and "Nicotinamide (NAM) rejuvenates ex vivo expanded natural killer cells and enhances their tumor killing capacity."

About GDA-201

Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results, as reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition1. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. For more information about GDA-201, please visit https://www.gamida-cell.com.

GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.